Stay up to date on COVID-19. Learn more
June 20, 2024
INESSS recommends including Tecvayli
On June 5, 2024, the Institut national d’excellence en santé et en services sociaux (INESSS) formally recommended to the Minister that Tecvayli (teclistamab) be included in the list of medications at treatment centres for the treatment of patients with relapsed or refractoryDisease that is unresponsive to standard treatments. multiple myeloma, subject to specific conditions. Read more here[…]
Learn moreJune 20, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
To date, identifying high-risk SMM patients remains an important clinicalInvolving direct observation of a patient. need. In this study, we present the 3-dimensional telomere profiling as a structural biomarker capable of stratifying SMM patients as a function of genomic instability Read more… […]
Learn moreMay 24, 2024
CCTG Recruiting for a Patient Representative Volunteer Role
The Canadian CancerA term for diseases in which malignant cells divide without control. Cancer cells can invade nearby tissues and spread through the bloodstream and lymphatic system to other parts of the body. Trial Group (CCTG) is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. We encourage applications from all qualified candidates and will accommodate applicants’ needs throughout all stages of the recruitment and[…]
Learn moreMay 14, 2024
Tecvayli was recommended for reimbursement by the CDA-AMC!
We are pleased to announce that on April 24th,TECVAYLI (teclistamab) was recommended for reimbursement by the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) of Canada’s Drug Agency (CDA-AMC)*– the first bispecific antibody for myeloma to be recommended for funding in Canada. The pERC’s final decision states that contingent on a price reduction, teclistamab should[…]
Learn moreMay 14, 2024
A Historic Turning Point: ODAC Unanimously Votes in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments
Minimal residual disease (MRD) testing has been recommended as an early endpoint in myeloma clinical trials by the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). If the recommendation is adopted by the FDA, it could lead to the accelerated approval of new treatments. Read more… […]
Learn moreApril 23, 2024
Postoperative Radiotherapy Following Spinal Surgery Safe, Effective in Multiple Myeloma
The current standard of spinal surgery followed by postoperative radiotherapy for osteolytic lesions of multiple myeloma (MM) is safe and associated with a low toxicity profile, according to research published in Strahlentherapie und Onkologie. Read more… […]
Learn moreMyeloma Canada updates
June 21, 2024
Martine Elias summarizes Real World Evidence (RWE) session at 2024 Myeloma Patients Europe Masterclass
As proud members of Myeloma Patients Europe (MPe), Myeloma Canada attended – and presented at – MPe’s annual Masterclass this past May. The Masterclass is a one-and-a-half-day educational program designed to: increase the knowledge and skills of MPe’s members; share the latest updates on myeloma and amyloidosisA condition in which myeloma light chains (Bence Jones proteins) are deposited in tissues and organs throughout the body. This occurs more commonly with lambda versus kappa Bence Jones proteins. In patients with amyloidosis, the light chain proteins bind to certain tissues such as heart, nerves and kidney rather than being excreted out of the body through the kidneys. diagnosisThe process of identifying a disease by its signs and symptoms., treatment and care; discuss the[…]
Learn moreMay 2, 2024
A round of applause for Martine and her new role!
It is with great joy and pleasure that we announce the advancement of our well-regarded Executive Director, Martine Elias, to the distinguished position of CEO at Myeloma Canada. Martine has been the driving force behind numerous achievements and advancements that have shaped Myeloma Canada into the leading organization it is today.[…]
Learn moreApril 23, 2024
A Letter To the Decision Makers Whose Decisions Can Impact The Lives Of Canadians Living with Cancer, To Those With The Power to Reshape The Landscape of Cancer Care in Canada
“Every hour in Canada tells a stark story. Twenty-seven individuals are thrust into the harsh reality of a cancer diagnosis, while ten others succumb to its merciless grip. Each day, 655 Canadians awaken to the daunting challenge ahead, while 238 bid farewell to their loved ones under the weight of[…]
Learn moreApril 23, 2024
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action
“Canada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to[…]
Learn moreApril 4, 2024
Myeloma Canada releases 2023 science and research impact report
2023 was a banner year for Myeloma Canada’s science and research funding initiatives. We not only introduced 3 new grants, but we entered into 10 important partnerships, each one focused on advancing essential Canadian myeloma research. We are thrilled to announce that we are currently supporting more than 28 exciting[…]
Learn moreFebruary 22, 2024
IMAGINE CANADA Organization Spotlight: Myeloma Canada
Established in 2005, Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. Their mission is to improve the lives of those affected by this disease by empowering our community through awareness, education, and advocacy programs, and by supporting clinical research to find[…]
Learn more